Zobrazeno 1 - 7
of 7
pro vyhledávání: '"I. A. Sklyanik"'
Autor:
E. A. Shestakova, I. A. Sklyanik, A. S. Panevina, A. V. Yurasov, Yu. I. Yashkov, M. S. Sineokaya, A. O. Gavrilova, V. V. Evdoshenko, V. V. Fedenko, N. S. Bordan, M. V. Shestakova
Publikováno v:
Сахарный диабет, Vol 26, Iss 5, Pp 446-454 (2023)
There are several models for predicting remission of type 2 diabetes mellitus (T2D) a year after bariatric surgery — DiaRem, ABSD, IMS, etc. However, these models cannot be used to predict the early normalization of glycemia (within a few months af
Externí odkaz:
https://doaj.org/article/3cd1928399ec497bb4297338bc492b2a
Feсal microbiota transplantation in the format of complex therapy in obesive siblings: clinical case
Autor:
E. V. Pokrovskaya, E. S. Zhgun, E. A. Shestakova, I. A. Sklyanik, I. V. Fedushkina, E. I. Olekhnovich, D. N. Konanov, D. A. Kardonsky, Yu. V. Kislun, E. A. Sorokina, L. I. Zilberman, N. V. Zaytseva, E. N. Ilina, V. M. Govorun, M. V. Shestakova
Publikováno v:
Сахарный диабет, Vol 25, Iss 4, Pp 405-417 (2022)
Obesity and associated metabolic diseases are often accompanied by changes in the gut microbiota leading to metagenome gene diversity decrease. Fecal microbiota transplantation (FMT) is one of the most effective methods for correcting the intestinal
Externí odkaz:
https://doaj.org/article/1921d8662c654e4ca3b0491ea026d1b9
Publikováno v:
Сахарный диабет, Vol 23, Iss 6, Pp 541-547 (2021)
Concerning the uncontrolled growth in the incidence of obesity and Type 2 Diabetes Mellitus (T2DM), numerous research have been carried out to study the pathogenetic mechanisms of progress of these diseases and development of new methods for their pr
Externí odkaz:
https://doaj.org/article/b6feeae3f36e45df88a2fbba4d96c784
Autor:
E. A. Shestakova, I. A. Sklyanik, A. S. Panevina, L. V. Nikankina, M. V. Shestakova, I. I. Dedov
Publikováno v:
Терапевтический архив, Vol 92, Iss 10, Pp 15-22 (2020)
Aim.Obese patients without diabetes present an interesting phenotype to explore protective mechanisms against type 2 diabetes (T2D) development. In our study we looked for specific hormonal features of obese patients without T2D. Materials and met
Externí odkaz:
https://doaj.org/article/e542d61f981246518d605deeea6397c7
Publikováno v:
Сахарный диабет, Vol 23, Iss 3, Pp 229-234 (2020)
Progressive decrease in the weight and functional reserve of β-cells is one of the main pathogenetic mechanisms of development of type 2 diabetes mellitus (DM2). The rate of progression of these processes is strictly individual, which largely determ
Externí odkaz:
https://doaj.org/article/62260d1579e642eebf8122da7935c08c
Publikováno v:
Терапевтический архив, Vol 91, Iss 10, Pp 34-38 (2019)
Aims. To compare glucose - lowering and weight reduction capacity of bypass operations (gastric bypass (GB), biliopancreatic diversion (BPD) vs GLP-1 agonist liraglutide 3.0 mg (models of maximum incretin effect) for 6 months. Materials and methods.
Externí odkaz:
https://doaj.org/article/b0598ed5f980450aad8287e6793e992b
Publikováno v:
Терапевтический архив, Vol 89, Iss 10, Pp 4-11 (2017)
A practitioner has a wide range of the hypoglycemic drugs for type 2 diabetes mellitus (T2DM) treatment, which can be used within a normal or near-normal range for long-term glycemic control. However, the question remains whether there are ways to ac
Externí odkaz:
https://doaj.org/article/23e9aec4ba6f4792aa576a81d484f3b3